IGF1R: Insulin-like growth factor 1 receptor
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Receptor tyrosine kinase which mediates actions of insulin- like growth factor 1 (IGF1).
- Drugs that act on it: 20
- With a US drug page: 3
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Masoprocol | Approved | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| Teprotumumab | Approved | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| Veligrotug | Approved | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| AEW-541 | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| AXL-1717 | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| BIIB-022 | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| BMS-754807 | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| Cixutumumab | — | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| Conteltinib | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| Dalotuzumab | — | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| Figitumumab | — | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| Ganitumab | — | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| Istiratumab | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| KW-2450 free base | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| Linsitinib | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| Mecasermin | — | Insulin-like growth factor I receptor agonist | Agonist | — |
| Mecasermin rinfabate | — | Insulin-like growth factor I receptor agonist | Agonist | — |
| PL-225B | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
| Robatumumab | — | Insulin-like growth factor I receptor antagonist | Antagonist | — |
| XL-228 | — | Insulin-like growth factor I receptor inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Growth delay due to insulin-like growth factor I resistance
- 0.81
- Abnormality of the skeletal system
- 0.61
- Gout
- 0.54
- Hereditary disease
- 0.52
- Neurodegenerative disease
- 0.52
- Type 2 diabetes mellitus
- 0.51
- Growth delay
- 0.50
- Smoking initiation
- 0.49
- Prostate carcinoma
- 0.49
- Neoplasm
- 0.44
Drugs and mechanisms are from ChEMBL CHEMBL1957 (CC BY-SA 3.0). Gene name, function (UniProt P08069, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets